Full Name: Bordetella Pertussis Toxin IgG ELISA Kit
Sample Type: Serum, Plasma
Sensitivity: 0.43 IU/ml
A major virulence factor is pertussis toxin, which impairs host immune cell function by inhibiting G protein signaling, leading to uncontrolled cAMP production in cells. This results in the symptoms of pertussis infection.
B. pertussis produces additional toxins like tracheal cytotoxin, which damages the ciliated airway epithelial cells. Fimbriae on the bacterial surface mediate adhesion to respiratory epithelium. Surface lipooligosaccharide (LOS) induces inflammatory responses. B. pertussis can evade host immunity through mechanisms including suppression of complement activity and antigenic variation of surface proteins.
Pertussis disease progresses through catarrhal, paroxysmal, and convalescent stages. It is highly contagious in the early catarrhal stage before the cough manifests. Pertussis spreads through respiratory droplets and has a high secondary attack rate. Coughing fits in the paroxysmal stage can lead to vomiting, exhaustion, and apnea. Infants are at greatest risk of severe and potentially fatal pertussis.
Widespread childhood vaccination with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine has substantially reduced pertussis incidence. However, DTaP effectiveness decreases over time, and pertussis now commonly affects adolescents and adults who can transmit the illness to unvaccinated infants. This resurgence demonstrates the need for improved pertussis vaccines and antibiotic prophylaxis for vulnerable contacts. Expanding Tdap booster uptake in older groups could lessen transmission.
Human Bordetella pertussis toxin IgG ELISA kit can be used for analysing amounts of human IgG antibodies against Bordetella toxin (Bordetella Toxin-IgG) using samples of serum and plasma. This assay has a minimum analytical sensitivity limit of 0.43 IU/ml.
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- Bordetella pertussis antigen coated microtiter strips.
- Calibrator A (Negative Control).
- Calibrator D (Positive Control).
- Calibrator C (Weak Positive Control).
- Calibrator B (Cut-Off Standard).
- Enzyme Conjugate.
- Sample Diluent.
- TMB Substrate.
- Washing Buffer (10x).
- Stop Solution.
The minimum detection sensitivity level of human IgG antibodies to Bordetella toxin (Bordetella Toxin-IgG) using current Bordetella pertussis toxin-IgG ELISA kit was 0.43 IU/ml. The dynamic range for this assay is 25.0 – 150.0 IU/ml.
- Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay. J Med Microbiol. (2013) 62 (Pt 9): 1281-9. Fry N.K., et al.
- Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays. Clin Vaccine Immunol. (2012) 19 (1): 64-72. Kapasi A., et al.
- Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect. (2005) 133 (4): 737-48. Versteegh F.G., et al.
- Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae. Clin Vaccine Immunol. (2014) 21 (7): 972-81. Salcedo-Rivillas C., et al.
- Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine. (2012) 30 (48): 6897-902. Barkoff A.M., et al.
OTHER RELATED ELISA KITS
Online Enquiry Form
"*" indicates required fields